{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:16:48Z","timestamp":1760267808322,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175007"],"award-info":[{"award-number":["175007"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11096-022-01491-8","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T19:39:21Z","timestamp":1665862761000},"page":"1442-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of miglustat versus symptomatic therapy of Niemann\u2013Pick disease type C"],"prefix":"10.1007","volume":"44","author":[{"given":"Medo","family":"Guti\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-1507","authenticated-orcid":false,"given":"Milo\u0161 N.","family":"Milosavljevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"issue":"8","key":"1491_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s11011-021-00842-0","volume":"36","author":"D Sitarska","year":"2021","unstructured":"Sitarska D, Tylki-Szyma\u0144ska A, \u0141ugowska A. Treatment trials in Niemann\u2013Pick type C disease. Metab Brain Dis. 2021;36(8):2215\u201321.","journal-title":"Metab Brain Dis"},{"issue":"1","key":"1491_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"13","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann\u2013Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50.","journal-title":"Orphanet J Rare Dis."},{"key":"1491_CR3","unstructured":"Bajwa H, Azhar W. Niemann\u2013Pick Disease. [Updated 2021 Jul 18]. In: StatPearls [Internet]. Treasure island (FL): StatPearls Publishing; 2022. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556129\/. Accessed 28 Feb 2022."},{"issue":"7","key":"1491_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.cell.2009.03.049","volume":"137","author":"HJ Kwon","year":"2009","unstructured":"Kwon HJ, Abi-Mosleh L, Wang ML, et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 2009;137(7):1213\u201324.","journal-title":"Cell"},{"issue":"40","key":"1491_CR5","doi-asserted-by":"publisher","first-page":"15287","DOI":"10.1073\/pnas.0807328105","volume":"105","author":"RE Infante","year":"2008","unstructured":"Infante RE, Wang ML, Radhakrishnan A, et al. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc Natl Acad Sci U S A. 2008;105(40):15287\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1491_CR6","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s10072-021-05337-5","volume":"42","author":"G Maresca","year":"2021","unstructured":"Maresca G, Formica C, Nocito V, et al. Neuropsychological assessment in Niemann\u2013Pick disease type C: a systematic review. Neurol Sci. 2021;42(8):3167\u201375.","journal-title":"Neurol Sci"},{"key":"1491_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier MT. Niemann\u2013Pick disease type C. Orphanet J Rare Dis. 2010;5:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"1491_CR8","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3390\/ijms21145059","volume":"21","author":"B Seker Yilmaz","year":"2020","unstructured":"Seker Yilmaz B, Baruteau J, Rahim AA, et al. Clinical and molecular features of early infantile Niemann Pick type C disease. Int J Mol Sci. 2020;21(14):5059.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1491_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3111\/13696990903245863","volume":"12","author":"J Imrie","year":"2009","unstructured":"Imrie J, Galani C, Gairy K, et al. Cost of illness associated with Niemann\u2013Pick disease type C in the UK. J Med Econ. 2009;12(3):219\u201329.","journal-title":"J Med Econ"},{"issue":"1","key":"1491_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","volume":"13","author":"M Pineda","year":"2018","unstructured":"Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann\u2013Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;13(1):140.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 3","key":"1491_CR11","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1590\/S1413-81232010000900019","volume":"15","author":"MV de Souza","year":"2010","unstructured":"de Souza MV, Krug BC, Picon PD, et al. High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders. Cien Saude Colet. 2010;15(Suppl 3):3443\u201354.","journal-title":"Cien Saude Colet"},{"issue":"1","key":"1491_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-017-0731-0","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, van der Ploeg AT, Kruijshaar ME, et al. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with pompe disease. Orphanet J Rare Dis. 2017;12(1):179.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1491_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1871530319666190807162344","volume":"20","author":"J Darb\u00e0","year":"2020","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Current status and use of resources of lysosomal storage diseases: analysis of a spanish claims database. Endocr Metab Immune Disord Drug Targets. 2020;20(2):263\u201370.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1491_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.vhri.2019.01.009","volume":"18","author":"M Davari","year":"2019","unstructured":"Davari M, Nabizadeh A, Kadivar M, et al. Healthcare resource utilization and the cost of care for mucopolysaccharidosis I patients in Iran. Value Health Reg Issues. 2019;18:165\u20139.","journal-title":"Value Health Reg Issues"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-7-76","volume":"7","author":"M Walterfang","year":"2012","unstructured":"Walterfang M, Chien YH, Imrie J, et al. Dysphagia as a risk factor for mortality in Niemann\u2013Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis. 2012;7:76.","journal-title":"Orphanet J Rare Dis"},{"key":"1491_CR16","unstructured":"WDI - Classifying countries by income. Available at: https:\/\/datatopics.worldbank.org\/world-development-indicators\/stories\/the-classification-of-countries-by-income.html. Accessed 05 Feb 2022."},{"key":"1491_CR17","unstructured":"Parliament of republic of serbia. health insurance law. Off Gaz RS. 2019. Available at: https:\/\/www.paragraf.rs\/propisi\/zakon_o_zdravstvenom_osiguranju.html. Accessed 05 Feb 2022."},{"key":"1491_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12883-015-0511-1","volume":"15","author":"J Imrie","year":"2015","unstructured":"Imrie J, Heptinstall L, Knight S, et al. Observational cohort study of the natural history of Niemann\u2013Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol. 2015;15:257.","journal-title":"BMC Neurol"},{"key":"1491_CR19","unstructured":"Republic Health Insurance Fund of Serbia. Rulebook on the prices of health services at the secondary and tertiary levels of health care. Off Gaz RS. 55\/2019, 53\/2021."},{"key":"1491_CR20","unstructured":"Republic Health Insurance Fund of Serbia. Rulebook on the List of Medicines Prescribed and Issued at the Expense of Compulsory Health Insurance Funds. Off Gaz RS. 43\/19, 55\/19, 56\/19-correction, 73\/19, 87\/19, 18\/20, 43 \/ 20, 108\/20, 49\/21, 51 \/ 21-correction and 60\/21."},{"key":"1491_CR21","unstructured":"The Government of the Republic of Serbia. Decision on the highest prices of prescription medicines for human use. Off Gaz RS. 48\/2021."},{"key":"1491_CR22","unstructured":"National Bank of Serbia. Interest rates. [Internet]. 2021. Available at: https:\/\/www.nbs.rs\/sr\/ciljevi-i-funkcije\/monetarna-politika\/kamatne-stope\/. Accessed 05 Feb 2022."},{"issue":"6","key":"1491_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40273-014-0147-9","volume":"32","author":"J Karnon","year":"2014","unstructured":"Karnon J, Ali Afzali Haji H. When to use discrete event simulation (DES) for the economic evaluation of health technologies a review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32(6):547\u201358.","journal-title":"Pharmacoeconomics."},{"key":"1491_CR24","unstructured":"Jankovic SM. Discrete-event simulation model for comparation of cost-effectiveness of miglustat versus symptomatic therapy in patients with Niemann\u2013Pick disease type C. 2022. Available at: https:\/\/drive.google.com\/file\/d\/1GshYch8Pz8ZvbKL6mJDrVHUGqqSBEWVV\/view?usp=sharing. Accessed 09 Aug 2022."},{"issue":"4","key":"1491_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ymgme.2019.02.004","volume":"126","author":"SE Bianconi","year":"2019","unstructured":"Bianconi SE, Hammond DI, Farhat NY, et al. Evaluation of age of death in Niemann\u2013Pick disease, type C: utility of disease support group websites to understand natural history. Mol Genet Metab. 2019;126(4):466\u20139.","journal-title":"Mol Genet Metab"},{"issue":"Pt 1","key":"1491_CR26","first-page":"120","volume":"130","author":"M Sevin","year":"2017","unstructured":"Sevin M, Lesca G, Baumann N, et al. The adult form of Niemann\u2013Pick disease type C. Brain. 2017;130(Pt 1):120\u201333.","journal-title":"Brain"},{"issue":"9","key":"1491_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann\u2013Pick c disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765\u201372.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1491_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2036.2008.03664.x","volume":"27","author":"GD Eslick","year":"2008","unstructured":"Eslick GD, Talley NJ. Dysphagia: epidemiology, risk factors and impact on quality of life\u2013a population-based study. Aliment Pharmacol Ther. 2008;27(10):971\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"16","key":"1491_CR29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/WNL.0000000000002041","volume":"85","author":"T Bremova","year":"2015","unstructured":"Bremova T, Malinov\u00e1 V, Amraoui Y, et al. Acetyl-dl-leucine in Niemann\u2013Pick type C: a case series. Neurology. 2015;85(16):1368\u201375.","journal-title":"Neurology"},{"issue":"4","key":"1491_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/epi4.12365","volume":"4","author":"M Vergeer","year":"2019","unstructured":"Vergeer M, de Ranitz-Greven WL, Neary MP, et al. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. Epilepsia Open. 2019;4(4):581\u201392.","journal-title":"Epilepsia Open"},{"issue":"9","key":"1491_CR31","doi-asserted-by":"publisher","first-page":"E3102","DOI":"10.3390\/ijerph17093102","volume":"17","author":"J Chittrakul","year":"2020","unstructured":"Chittrakul J, Siviroj P, Sungkarat S, et al. Multi-system physical exercise intervention for fall prevention and quality of life in pre-frail older adults: a randomized controlled trial. Int J Environ Res Public Health. 2020;17(9):E3102.","journal-title":"Int J Environ Res Public Health"},{"key":"1491_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-7525-12-6","volume":"12","author":"J Roberts","year":"2014","unstructured":"Roberts J, Lenton P, Keetharuth AD, et al. Quality of life impact of mental health conditions in England: results from the adult psychiatric morbidity surveys. Health Qual Life Outcomes. 2014;12:6.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"1491_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1017\/S1041610214000775","volume":"26","author":"CM Giebel","year":"2014","unstructured":"Giebel CM, Sutcliffe C, Stolt M, et al. Deterioration of basic activities of daily living and their impact on quality of life across different cognitive stages of dementia: a European study. Int Psychogeriatr. 2014;26(8):1283\u201393.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"1491_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12876-021-01673-0","volume":"21","author":"E Majsiak","year":"2021","unstructured":"Majsiak E, Choina M, Golicki D, et al. The impact of symptoms on quality of life before and after diagnosis of coeliac disease: the results from a Polish population survey and comparison with the results from the United Kingdom. BMC Gastroenterol. 2021;21(1):99.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"1491_CR35","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/ajmg.a.61197","volume":"179","author":"JW Varni","year":"2019","unstructured":"Varni JW, Nutakki K, Swigonski NL. Speech difficulties and patient health communication mediating effects on worry and health-related quality of life in children, adolescents, and young adults with Neurofibromatosis type 1. Am J Med Genet A. 2019;179(8):1476\u201382.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1491_CR36","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care."},{"issue":"1","key":"1491_CR37","first-page":"48","volume":"41","author":"V Cupurdija","year":"2015","unstructured":"Cupurdija V, Lazic Z, Petrovic M, et al. Community-acquired pneumonia: economics of inpatient medical care vis-\u00e0-vis clinical severity. J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia. 2015;41(1):48\u201357.","journal-title":"J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia"},{"issue":"11","key":"1491_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1542\/hpeds.2016-0064","volume":"6","author":"AW Hirsch","year":"2016","unstructured":"Hirsch AW, Monuteaux MC, Fruchtman G, et al. Characteristics of children hospitalized with aspiration pneumonia. Hosp Pediatr. 2016;6(11):659\u201366.","journal-title":"Hosp Pediatr"},{"key":"1491_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vhri.2021.05.007","volume":"27","author":"I Mikuli\u0107","year":"2022","unstructured":"Mikuli\u0107 I, Liki\u0107 R, Jankovi\u0107 SM. Cost-effectiveness of zonisamide versus levetiracetam in newly diagnosed focal onset epilepsy in Serbia. Value Health Reg Issues. 2022;27:49\u201357.","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"1491_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00198-015-3350-4","volume":"27","author":"JC Davis","year":"2016","unstructured":"Davis JC, Dian L, Khan KM, et al. Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27(3):943\u201351.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"3","key":"1491_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13651501.2020.1767788","volume":"24","author":"NP Mari\u0107","year":"2020","unstructured":"Mari\u0107 NP, Andri\u0107Petrovi\u0107 S, Jeroti\u0107 S, et al. Maintenance phase treatment of psychotic disorders in outpatients from Serbia\u2013focus on long-term benzodiazepine use. Int J Psychiatry Clin Pract. 2020;24(3):315\u201321.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"8","key":"1491_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/gps.2610","volume":"26","author":"A Wimo","year":"2011","unstructured":"Wimo A, J\u00f6nsson L, Gustavsson A, et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry. 2011;26(8):825\u201332.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"1491_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1046\/j.1365-2036.1997.00262.x","volume":"11","author":"NE Wells","year":"1997","unstructured":"Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11(6):1019\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"1491_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12876-015-0398-8","volume":"15","author":"CE Flik","year":"2015","unstructured":"Flik CE, Laan W, Smout AJPM, et al. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol. 2015;15:168.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"1491_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3109\/17549507.2015.1126640","volume":"18","author":"R Kaipa","year":"2016","unstructured":"Kaipa R, Peterson AM. A systematic review of treatment intensity in speech disorders. Int J Speech Lang Pathol. 2016;18(6):507\u201320.","journal-title":"Int J Speech Lang Pathol"},{"issue":"1","key":"1491_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-019-0996-6","volume":"14","author":"M Pineda","year":"2019","unstructured":"Pineda M, Jur\u00ed\u010dkov\u00e1 K, Karimzadeh P, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann\u2013Pick disease type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1491_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","volume":"15","author":"MC Patterson","year":"2020","unstructured":"Patterson MC, Mengel E, Vanier MT, et al. Treatment outcomes following continuous miglustat therapy in patients with Niemann\u2013Pick disease type C: a final report of the NPC registry. Orphanet J Rare Dis. 2020;15(1):104.","journal-title":"Orphanet J Rare Dis"},{"key":"1491_CR48","unstructured":"Zavesca prices, coupons & patient assistance programs. Drugs.com. Available at: https:\/\/www.drugs.com\/price-guide\/zavesca. Accessed 05 Feb 2022."},{"key":"1491_CR49","unstructured":"Statistical office of the republic of Serbia 2022 . Available at: https:\/\/data.stat.gov.rs\/Home\/Result\/09020101?languageCode=sr-Cyrl. Accessed 12 Feb 2022."},{"key":"1491_CR50","unstructured":"Food and drug administration. ZAVESCA\u00ae (miglustat) capsules, for oral use. 2003. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021348s010lbl.pdf. Accessed 12 Feb 2022"},{"issue":"22","key":"1491_CR51","first-page":"360","volume":"3","author":"A Santos-Lozano","year":"2015","unstructured":"Santos-Lozano A, Villamandos Garc\u00eda D, Sanchis-Gomar F, et al. Niemann\u2013Pick disease treatment: a systematic review of clinical trials. Ann Transl Med. 2015;3(22):360.","journal-title":"Ann Transl Med"},{"issue":"12","key":"1491_CR52","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1001\/jamaneurol.2020.3241","volume":"77","author":"BI Solomon","year":"2020","unstructured":"Solomon BI, Smith AC, Sinaii N, et al. Association of miglustat with swallowing outcomes in Niemann\u2013Pick disease, type C1. JAMA Neurol. 2020;77(12):1564\u20138.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1491_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-018-0913-4","volume":"13","author":"Y Nadjar","year":"2018","unstructured":"Nadjar Y, H\u00fctter-Moncada AL, Latour P, et al. Adult Niemann\u2013Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis. 2018;13(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1491_CR54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann\u2013Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;99(4):351\u20137.","journal-title":"Mol Genet Metab"},{"issue":"20","key":"1491_CR55","first-page":"30437","volume":"S1695\u20134033","author":"A Caso-Gonz\u00e1lez","year":"2020","unstructured":"Caso-Gonz\u00e1lez A, N\u00fa\u00f1ez-Rodr\u00edguez J, Nebot-Villacampa MJ, et al. Experiencia cl\u00ednica con medicamentos hu\u00e9rfanos para enfermedades raras metab\u00f3licas [clinical experience with orphan drugs for rare metabolic diseases]. An Pediatr (Engl Ed). 2020;S1695\u20134033(20):30437\u20139.","journal-title":"An Pediatr (Engl Ed)"},{"issue":"8","key":"1491_CR56","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-016-0842-x","volume":"18","author":"I Holmerov\u00e1","year":"2017","unstructured":"Holmerov\u00e1 I, Hort J, Rusina R, et al. Costs of dementia in the Czech Republic. Eur J Health Econ. 2017;18(8):979\u201386.","journal-title":"Eur J Health Econ"},{"key":"1491_CR57","unstructured":"Statista. Health, Pharma & Medtech. Health Professionals & Hospitals. Average cost of inpatient day at U.S. hospitals in 2019, by hospital type. Available at: https:\/\/www.statista.com\/statistics\/630443\/inpatient-day-hospital-costs-in-us-by-nonprofit-or-profit\/. Accessed 28 Feb 2022."},{"key":"1491_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eurpsy.2017.10.008","volume":"48","author":"G Kov\u00e1cs","year":"2018","unstructured":"Kov\u00e1cs G, Alm\u00e1si T, Millier A, et al. Direct healthcare cost of schizophrenia\u2013European overview. Eur Psychiatry. 2018;48:79\u201392.","journal-title":"Eur Psychiatry"},{"key":"1491_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jsr.2016.05.001","volume":"58","author":"ER Burns","year":"2016","unstructured":"Burns ER, Stevens JA, Lee R. The direct costs of fatal and non-fatal falls among older adults\u2013United States. J Safety Res. 2016;58:99\u2013103.","journal-title":"J Safety Res"},{"issue":"Suppl 1","key":"1491_CR60","doi-asserted-by":"publisher","first-page":"e000794","DOI":"10.1136\/rmdopen-2018-000794","volume":"4","author":"S Cannizzo","year":"2018","unstructured":"Cannizzo S, Lorenzoni V, Palla I, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018;4(Suppl 1):e000794.","journal-title":"RMD Open"},{"issue":"1","key":"1491_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-016-0528-6","volume":"11","author":"MK Javaid","year":"2016","unstructured":"Javaid MK, Forestier-Zhang L, Watts L, et al. The RUDY study platform\u2014a novel approach to patient driven research in rare musculoskeletal diseases. Orphanet J Rare Dis. 2016;11(1):150.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1491_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.23672","volume":"72","author":"SM Murphy","year":"2012","unstructured":"Murphy SM, Puwanant A, Griggs RC. Consortium for clinical investigations of neurological channelopathies (CINCH) and Inherited neuropathies consortium (INC) Consortia of the rare disease clinical research network. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol. 2012;72(4):481\u201390.","journal-title":"Ann Neurol."},{"issue":"1","key":"1491_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.hlpt.2021.02.002","volume":"10","author":"AR Sequeira","year":"2021","unstructured":"Sequeira AR, Mentzakis E, Archangelidi O, et al. The economic and health impact of rare diseases: a meta-analysis. Health Policy Technol. 2021;10(1):32\u201344.","journal-title":"Health Policy Technol"},{"issue":"1","key":"1491_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5152\/balkanmedj.2015.15185","volume":"33","author":"G Iskrov","year":"2016","unstructured":"Iskrov G, Stefanov R. Criteria for drug reimbursement decision-making: an emerging public health challenge in Bulgaria. Balkan Med J. 2016;33(1):27\u201335.","journal-title":"Balkan Med J"},{"issue":"7159","key":"1491_CR65","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/449176a","volume":"449","author":"PM Danzon","year":"2007","unstructured":"Danzon PM. At what price? Nature. 2007;449(7159):176\u20139.","journal-title":"Nature"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01491-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T23:08:15Z","timestamp":1701212895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01491-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01491-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}